Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
37.08
-0.38 (-1.01%)
At close: Mar 6, 2026, 4:00 PM EST
37.80
+0.72 (1.94%)
After-hours: Mar 6, 2026, 7:36 PM EST

Cogent Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
63.5843.2834.3826.2119.64
Research & Development
269.78232.66173.76121.6355.91
Total Operating Expenses
333.36275.94208.13147.8475.55
Operating Income
-333.36-275.94-208.13-147.84-75.55
Interest Income
14.6918.0913.083.990.47
Interest Expense
-3.06----
Other Non-Operating Income (Expense)
7.161.990.942.252.47
Total Non-Operating Income (Expense)
18.7920.0814.026.242.94
Pretax Income
-314.58-255.86-194.11-141.6-72.62
Net Income
-328.94-255.86-192.41-140.24-72.27
Net Income to Common
-328.94-255.86-192.41-140.24-72.27
Shares Outstanding (Basic)
129104805939
Shares Outstanding (Diluted)
129104805939
Shares Change (YoY)
24.11%30.38%35.61%51.66%249.52%
EPS (Basic)
-2.16-1.94-1.94-1.73-1.87
EPS (Diluted)
-2.16-1.94-1.94-1.73-1.87
Free Cash Flow
-266-208.36-156.42-125.5-60.48
Free Cash Flow Per Share
-2.06-2.01-1.96-2.14-1.56
EBITDA
-328.78-271.59-204.54-141.96-73.56
EBIT
-333.36-275.94-208.13-147.84-75.55
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q